Skip to content
HowShorted

Esperion Therapeutics, Inc. short interest in 2020

In 2020, Esperion Therapeutics, Inc.'s disclosed short interest ran from 17.67% of shares outstanding on 15 Jan 2020 to 38.68% on 31 Dec 2020, a change of +21.01 percentage points. The year's high was 41.56% on 31 Aug 2020 and its low 17.67% on 15 Jan 2020, averaging 32.07% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 26.77 days on 30 Sep 2020. Full history: Esperion Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Esperion Therapeutics, Inc. in 2020

2020 in figures

Start of year
17.67% (15 Jan 2020)
End of year
38.68% (31 Dec 2020)
Change
+21.01 pp
High
41.56% (31 Aug 2020)
Low
17.67% (15 Jan 2020)
Average
32.07%
Highest days to cover
26.77 (30 Sep 2020)
SEC filings marked
8

Every report in 2020

Esperion Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202017.67%13.04
31 Jan 202017.89%9.56
14 Feb 202019.10%7.04
28 Feb 202024.91%4.6510-K filed, results (8-K)
13 Mar 202022.57%7.20
31 Mar 202025.46%7.81
15 Apr 202027.65%11.20
30 Apr 202028.20%14.35
15 May 202030.22%12.2110-Q filed, results (8-K)
29 May 202029.42%12.37
15 Jun 202033.92%16.34
30 Jun 202036.67%14.86
15 Jul 202037.96%24.85
31 Jul 202039.40%19.23
14 Aug 202039.55%13.3510-Q filed, results (8-K)
31 Aug 202041.56%20.90
15 Sep 202040.15%25.58
30 Sep 202040.03%26.77
15 Oct 202036.40%22.48
30 Oct 202036.16%23.45
13 Nov 202034.75%7.8510-Q filed, results (8-K)
30 Nov 202035.09%17.61
15 Dec 202036.29%25.91
31 Dec 202038.68%17.36

See also: Esperion Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.